Preview

Rational Pharmacotherapy in Cardiology

Advanced search

MODERN POSSIBILITIES OF ACHIEVING TARGET BLOOD PRESSURE LEVEL IN HYPERTENSIVE PATIENTS IN OUTPATIENT PRACTICE: THE LEADER STUDY RESULTS

https://doi.org/10.20996/1819-6446-2018-14-1-12-20

Full Text:

Abstract

Aim. To study the efficacy and safety of the use of hydrochlorothiazide/losartan or amlodipine/losartan fixed combinations in patients with arterial hypertension (HT) in real clinical practice.

Material and methods. A total of 13,863 adult patients with HT were enrolled into the observational study. One month ago, according to the indications, they were prescribed therapy with amlodipine/losartan (5/50, 10/50, 5/100, 10/100 mg) or hydrochlorothiazide/losartan (12.5/50, 12.5/100, 25/100 mg). The study included only those patients who did not reach the target blood pressure (BP) level in previous therapy, or were not treated earlier. The study duration was 3 months.

Results. 79.17% of patients reached the target BP level by the end of the study after 3 months. High efficacy of HT treatment persisted in concomitant diseases. The target BP level was achieved in 76.42% of patients with coronary heart disease, 73.98% of patients with diabetes and 78.34% of patients with chronic obstructive pulmonary disease. According to the results of the questionnaire on a 7-point scale, 93% of doctors gave the maximum score on the treatment effectiveness and 97% – on the treatment safety. During the entire treatment period, no one patient discontinued participation in the study due to adverse events.

 Conclusion. The study demonstrated high efficacy and safety of HT patients treatment with hydrochlorothiazide/losartan and amlodipine/losartan fixed combinations in real clinical practice. The majority of patients who were previously treated ineffectively or did not receive treatment achieved adequate BP control during treatment with hydrochlorothiazide/losartan or amlodipine/losartan fixed combinations. 

About the Authors

D. V. Nebieridze
National Medical Research Center for Preventive Medicine
Russian Federation

David V. Nebieridze – MD, PhD, Professor, Head of Department of Metabolic Disorders Prevention 

Petroverigsky per. 10, Moscow, 101990



A. S. Safaryan
National Medical Research Center for Preventive Medicine
Russian Federation

Anush S. Safaryan – MD, PhD, Leading Researcher, Department of Metabolic Disorders Prevention 

Petroverigsky per. 10, Moscow, 101990



V. A. Vygodin
National Medical Research Center for Preventive Medicine
Russian Federation

Vladimir A. Vygodin – Senior Researcher, Laboratory of Biostatistics 

Petroverigsky per. 10, Moscow, 101990



O. M. Drapkina
National Medical Research Center for Preventive Medicine
Russian Federation

Oksana M. Drapkina – MD, PhD, Professor, Corresponding Member of the Russian Academy of Sciences, Director of National Medical Research Center for Preventive Medicine 

Petroverigsky per. 10, Moscow, 101990



S. A. Boytsov
National Medical Research Center of Cardiology
Russian Federation

Sergey A. Boytsov – MD, PhD, Professor, Corresponding Member of the Russian Academy of Sciences, General Director of NationalMedical Research Center of Cardiology 

Tretya Cherepkovskaya ul. 15a, Moscow, 121552



References

1. 2016 European Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2016;37:2315-81. doi:10.1093/eurheartj/ehw106

2. 2013 ESH/ESC Guidelines for the management of arterial hypertension. J Hypertens. 2013;31(7):1281-357. doi: 10.1097/01.hjh.0000431740.32696.

3. Chazova I.E., Zhernakova Yu.V., Oschepkova E.V. et al. The prevalence of risk factors for cardiovascular diseases in the Russian population of patients with arterial hypertension. Cardiology. 2014;10:412. (In Russ.) [Чазова И.Е., Жернакова Ю.В., Ощепкова Е.В. и др. Распространенность факторов риска сердечно-сосудистых заболеваний в российской популяции больных артериальной гипертонией. Кардиология. 2014;10:4-12]. doi: 10.18565/cardio.2014.10.4-12

4. Diagnosis and treatment of arterial hypertension (Clinical recommendations). Kardiologicheskij Vestnik. 2015;10(1):5-31. (In Russ.) [Диагностика и лечение артериальной гипертонии (Клинические рекомендации). Кардиологический Вестник. 2015;10(1):5-31].

5. Mancia G, De Backer G, Dominiczak A, et al. Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25(6):1105-87. doi: 10.1097/HJH.0b013e3281fc975a

6. Wolf-Maier K, Cooper RS, Banegas JR, et al. Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. JAMA. 2003;289:2363-9. doi: 10.1001/jama.289.18.2363

7. Lawes C, Vander Hoorn S, Rodgers A; International Society of Hypertension. Global burden of bloodpressurerelated disease, 2001. Lancet. 2008;371:1513-8. doi: 10.1016/S0140-6736(08)60655-8.

8. Wolf-Maier K, Cooper RS, Kramer H, et al. Hypertension Treatment and Control in Five European Countries, Canada, and the United States. Hypertension. 2004;43(1):10-7. doi: 10.1161/01.HYP.0000103630.72812.10

9. Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903-13. doi: 10.1016/S0140-6736(02)11911-8.

10. Ostroumova OD, Bondarets OV, Kopchenov II, Guseva TF From the choice of an antihypertensive drug to the selection of fixed combinations of antihypertensive drugs: a paradigm shift. Sistemnye Gipertenzii. 2015; 12 (4): 23-9 (In Russ.) [Остроумова О.Д., Бондарец О.В., Копченов И.И, Гусева Т.Ф. От выбора антигипертензивного препарата – к выбору фиксированных комбинаций антигипертензивных препаратов: смена парадигм. Системные Гипертензии. 2015;12(4):23-9].


For citation:


Nebieridze D.V., Safaryan A.S., Vygodin V.A., Drapkina O.M., Boytsov S.A. MODERN POSSIBILITIES OF ACHIEVING TARGET BLOOD PRESSURE LEVEL IN HYPERTENSIVE PATIENTS IN OUTPATIENT PRACTICE: THE LEADER STUDY RESULTS. Rational Pharmacotherapy in Cardiology. 2018;14(1):12-20. (In Russ.) https://doi.org/10.20996/1819-6446-2018-14-1-12-20

Views: 305


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)